ISTH 2022
July 9-13, London
Read more
News
- Aplagon Publishes New Data in Prestigious Journal of Cardiovascular Pharmacology 1 September 2021 - HELSINKI, September 1, 2021. Aplagon Oy (“Aplagon”), the Finnish pharmaceutical development company developing first-in-class vasculoprotective antithrombotic compounds to treat vascular injury related blood vessel occlusions and tissue damage, today announced the publication of new data as well as an accompanying commentary by third-party experts in the leading, peer-reviewed Journal of… read more »
- Aplagon Closes Oversubscribed EUR 2.2M Funding Round 28 May 2021 - HELSINKI, May 28, 2021. Aplagon Oy (“Aplagon”), the Finnish pharmaceutical development company developing first-in-class vasculoprotective antithrombotic compounds to treat vascular injury related blood vessel occlusions and tissue damage, today announced the closing of a EUR 2.2 million funding round. The fundraise was arranged in collaboration with Invesdor Group and was… read more »
- Aplagon Partners with Cadila Pharmaceuticals to Develop and Commercialize APAC First-in-Class Antithrombotics for the Prevention of Blood Vessel Occlusions Related to Vascular Interventions 19 September 2017 - HELSINKI AND STOCKHOLM, September 19, 2017. Aplagon Oy (“Aplagon”) and Cadila Pharmaceuticals Sweden AB today announced a development and commercialization agreement for Aplagon’s lead APAC product. APACs are proprietary, locally acting, potent antithrombotic products, which target blood vessel wall injury. Under the agreement, Cadila Pharmaceuticals Sweden AB together with its… read more »
Events
Aplagon will be represented at the following partnering or scientific meetings.
- ISTH 2022
- LSX World 2022
LSX World 2022
May 10-11, London (in-person)
May 16-20 (online)
Read more